The role of transport exchanges of neuroactive solutes across the blood–brain barrier (BBB)
is increasingly recognized. To take full advantage of genetically altered mouse models of …

Amyloid-β (Aβ) accumulation in Alzheimer's disease (AD) and cerebral amyloid angiopathy
(CAA) is likely caused by the impairment of its brain clearance that partly occurs through the …

The clearance of amyloid beta (Aβ) from the brain represents a novel therapeutic target for
Alzheimer's disease. Conflicting data exist regarding the contribution of adenosine …

The accumulation of beta‐amyloid [Aβ] within senile plaques [SP] is characteristic of these
lesions in Alzheimer's disease. The accumulation of Aβ42, in particular, in the superior …

Though Alzheimer's disease (AD) has been studied for more than a century, to date, no drug
has provided a definitive cure. The slow development of the disease and the time lag …

The blood-brain barrier (BBB) is the multicellular interface located between the peripheral
circulation and the brain parenchyma. BBB dysfunction is reported in many CNS diseases …

Successful prevention and treatment of late-onset Alzheimer's disease (AD) is a high priority
for industrialized societies where the incidence is growing rapidly. Much of the underlying …

The origin of amyloid β (Aβ) deposited in brain and cerebral blood vessels of patients with
Alzheimer′ s Disease (AD) is not known. In this study, we tested whether soluble Aβ (sAβ) …

Alzheimer's disease (AD) is a chronic neurodegenerative disorder characterized by the
pathological accumulation of amyloid beta (Aβ) peptides and neurofibrillary tangles …

Vasoactive regulatory and transport proteins can modify the transendothelial blood-brain
barrier (BBB) transport of beta-amyloid. Dysfunction of one or more of these proteins is …